Skip to content

Goodwill at other companies

Eli Lilly logo
Eli LillyLLY
$6.13B+6.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$44M-0.9%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$62.48M+3.0%
LQD
Liquidia CorporationLQDA
$3.9M0.0%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$593.8M-0.6%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$582.32M+39.7%

Other financials

Income statement

See full
Revenue$83.1M+38.3%
Gross profit$72.6M+41.2%
Operating income$7.9M+356%
Net income$2.2M+124%
EPS (diluted)$0.01+117%

Balance sheet

See full
Cash & equivalents$111.8M+91.2%
Total debt$258.6M-3.8%
Total equity$13.0M+137%
Total assets$392.0M+24.3%

Cash flow

See full
Operating cash flow$9.9M+198%
CapEx$131.0K
Free cash flow-$29.1M

Valuation

See full
Market cap$1.28B+18.3%
Enterprise value$1.42B+8.7%
P/E106.4×
P/S4.1×-0.8×

Profitability

See full
Gross margin85.9%+3.7pp
Operating margin11.4%+7.7pp
Net margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-209.8%
Debt / equity19.9×
Current ratio2.1×+0.4×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s goodwill?
Xeris Biopharma Holdings, Inc. (XERS) reported goodwill of $22.86M in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s goodwill changed year-over-year?
Xeris Biopharma Holdings, Inc.'s goodwill decreased by 0.0% year-over-year, from $22.86M to $22.86M.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.